


LY 2389575 hydrochloride

Chemical Properties

CAS No. :	885104-09-6
Formula:	C15H16BrCl3N4
Molecular Weight:	438.58
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	LY2389575 hydrochloride is an mGlu3 negative allosteric modulator (NAM) that is selective and non-competitive, with an IC50 value of 190 nM. LY2389575 hydrochloride induces an increase in the level of Mrc1, which amplifies the toxicity of β -amyloid (A β), and can be used to study Alzheimer's disease. It can be used to study Alzheimer's disease.
Targets(IC50)	Beta Amyloid,GluR
In vitro	LY2389575 hydrochloride (5 μ M; 1 h) induces an increase in Mrc1 levels in microglial cells.[2]

Solubility Information

Solubility	DMSO: 90 mg/mL (205.21 mM),Sonication and heating to 60°C are recommended. Methanol: 7.5 mg/mL (17.1 mM),Sonication and heating to 60°C are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.52 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2801 mL	11.4004 mL	22.8009 mL
5 mM	0.456 mL	2.2801 mL	4.5602 mL
10 mM	0.228 mL	1.140 mL	2.2801 mL
50 mM	0.0456 mL	0.228 mL	0.456 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Caraci F, et al. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. *Mol Pharmacol.* 2011;79(3):618-626.

Zinni M, et al. mGlu3 receptor regulates microglial cell reactivity in neonatal rats. *J Neuroinflammation.* 2021;18(1):13.

Srivastava A, et al. Metabotropic Glutamate Receptors in Alzheimer's Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future. *J Alzheimers Dis.* 2020;78(4):1345-1361.

Sheffler DJ, et al. Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. *Bioorg Med Chem Lett.* 2012;22(12):3921-3925.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481